AB InBev vs Altria

AB InBev and Altria are compared to illuminate differences in business models, financial performance, and market context. This page outlines how each company creates value, allocates capital, and operates within its regulatory and competitive landscape, in clear, accessible language for context and understanding. Educational content, not financial advice.

AB InBev and Altria are compared to illuminate differences in business models, financial performance, and market context. This page outlines how each company creates value, allocates capital, and oper...

Comparison Snapshot

Key Financial Metrics

BUD

Metric

MO

$125.40B

Market Cap

$105.72B

9.77%

Potential Profit

-0.84%

Buy

Analyst Rating

Hold

Why It's Moving

BUD Stock Climbs Amid Steady Gains and Recent Company Updates

Stock rose 0.316% on Jan 23, extending a short-term rising trend with analysts projecting further upside potential.
Multiple press releases issued this month, including on Jan 21 and Jan 19, highlighting company initiatives and keeping investors engaged.
Positioned at an attractive P/E ratio below sector and market averages, drawing attention amid stabilizing consumer staples trends.

Sentiment:

🐃Bullish

Altria's Stock Powers Through Seven Straight Gains on FDA Green Light Momentum.

FDA Marketing Granted Orders for six on! oral nicotine pouches unlock new growth avenues, easing pressures from declining cigarette volumes.
UBS upgrades to Buy with $63 target, betting the worst of volume erosion is over as industry trends stabilize in 2026.
Stock surged over 10% across the prior six sessions, with Friday's 0.42% pop to $61.84 reflecting broad market optimism.

Sentiment:

🐃Bullish

BUD Stock Climbs Amid Steady Gains and Recent Company Updates

Stock rose 0.316% on Jan 23, extending a short-term rising trend with analysts projecting further upside potential.
Multiple press releases issued this month, including on Jan 21 and Jan 19, highlighting company initiatives and keeping investors engaged.
Positioned at an attractive P/E ratio below sector and market averages, drawing attention amid stabilizing consumer staples trends.

Sentiment:

🐃Bullish

Altria's Stock Powers Through Seven Straight Gains on FDA Green Light Momentum.

FDA Marketing Granted Orders for six on! oral nicotine pouches unlock new growth avenues, easing pressures from declining cigarette volumes.
UBS upgrades to Buy with $63 target, betting the worst of volume erosion is over as industry trends stabilize in 2026.
Stock surged over 10% across the prior six sessions, with Friday's 0.42% pop to $61.84 reflecting broad market optimism.

Sentiment:

🐃Bullish

Investment Analysis

AB InBev

BUD

Pros

Portfolio of globally recognised beer brands provides stable cash flows and resilience against regional downturns.
Consistent dividends and large-scale operations support shareholder returns, with recent margin expansion despite top-line pressures.
Ongoing innovation and packaging launches aim to capture growth in both beer and non-alcoholic segments, including expansion into new formats and markets.

Considerations

Recent quarterly results show significant volume declines in key markets like China, leading to double-digit drops in revenue and EBITDA.
Exposure to emerging markets increases vulnerability to currency fluctuations and local economic instability.
Intense competition and shifting consumer preferences toward craft and non-alcoholic beverages challenge traditional beer growth.

Altria

MO

Pros

Strong free cash flow generation from core tobacco operations enables significant share buybacks and consistent dividend payments.
Diversified product portfolio, including reduced-risk tobacco products, provides some insulation against long-term cigarette decline.
Recent monetisation of a portion of its large Anheuser-Busch InBev stake demonstrates ability to unlock value from non-core investments.

Considerations

Core tobacco business faces secular decline in cigarette volumes due to health concerns and regulatory pressures, especially in developed markets.
Heavy reliance on the US market increases exposure to domestic regulatory and litigation risks.
Recent share sales in Anheuser-Busch InBev reduce a historically stable source of dividend income and capital gains.

Related Market Insights

Beverage Stocks: Could Economic Headwinds Hit Returns?

Economic headwinds are reshaping consumer spending on beverages. Discover how this impacts premium vs. value brands & find investment opportunities in the sector.

Aimee Silverwood | Financial Analyst

October 7, 2025

Read Insight

Related Market Insights

Beverage Stocks: Could Economic Headwinds Hit Returns?

Economic headwinds are reshaping consumer spending on beverages. Discover how this impacts premium vs. value brands & find investment opportunities in the sector.

Aimee Silverwood | Financial Analyst

October 7, 2025

Read Insight

About The Companies

AB InBev (BUD)

Anheuser‑Busch InBev SA/NV (BUD) is one of the world’s largest brewers, owning a broad portfolio of global and local beer brands including Budweiser, Stella Artois and Corona, and operating across Europe, the Americas, Africa and Asia. With a market capitalisation of about $110.8bn, the group benefits from scale, wide distribution networks and strong marketing capabilities that can support steady revenue streams. Investors should note the capital‑intensive nature of the business and historically elevated net debt following major acquisitions; free cash flow and deleveraging are key financial priorities. Performance is influenced by commodity costs, currency movements, changing consumer tastes and regulatory factors. The company has paid dividends in the past, but payouts and buybacks depend on cash generation and board decisions. This summary is educational only and not personalised advice; suitability depends on your objectives, risk tolerance and circumstances.

Altria (MO)

Altria Group Inc. (MO) is one of the largest US tobacco companies, best known for its ownership of Philip Morris USA, a portfolio of smokeless and cigar businesses, a wine subsidiary and strategic investments in reduced‑risk product makers. With a market capitalisation of about $107.1 billion, Altria is notable for its long history of dividend payments and cash generation from cigarette sales, which remain a major profit driver despite declining smoking prevalence. Key considerations for investors include regulatory and litigation risk, excise taxes, shifting consumer preferences toward nicotine alternatives, and ESG-related pressures. The company has invested in vaping and cannabis ventures historically, reflecting a strategic interest in product diversification, though outcomes have varied. Dividends and yield often attract income-focused investors, but dividend levels are not guaranteed and can change. This summary is educational only—not personalised financial advice—and investors should weigh risks, long‑term trends and suitability before considering exposure.

AB InBev (BUD) Next Earnings Date

Anheuser-Busch InBev (BUD) has scheduled its next earnings report for February 25, 2026, prior to market open. This release will cover the full-year 2025 results, consistent with the company's historical late-February reporting for Q4. Several sources align on or near this date, reflecting BUD's quarterly pattern.

Altria (MO) Next Earnings Date

Altria Group (MO) is scheduled to report its next earnings on January 29, 2026 before market open, covering the Q4 2025 and full-year 2025 results. This earnings announcement will include the company's financial performance for the fourth quarter and complete fiscal year 2025. The earnings conference call is set for 9:00 AM ET on that date, where management will discuss results and provide forward guidance. Analysts are currently projecting an EPS of approximately $1.31 for the quarter.

AB InBev (BUD) Next Earnings Date

Anheuser-Busch InBev (BUD) has scheduled its next earnings report for February 25, 2026, prior to market open. This release will cover the full-year 2025 results, consistent with the company's historical late-February reporting for Q4. Several sources align on or near this date, reflecting BUD's quarterly pattern.

Altria (MO) Next Earnings Date

Altria Group (MO) is scheduled to report its next earnings on January 29, 2026 before market open, covering the Q4 2025 and full-year 2025 results. This earnings announcement will include the company's financial performance for the fourth quarter and complete fiscal year 2025. The earnings conference call is set for 9:00 AM ET on that date, where management will discuss results and provide forward guidance. Analysts are currently projecting an EPS of approximately $1.31 for the quarter.

Which Baskets Do They Appear In?

Beverage Stocks: Could Economic Headwinds Hit Returns?

Constellation Brands surpassed Q2 earnings expectations but trimmed its full-year forecast, signaling that economic headwinds are impacting consumer spending on alcohol. This development suggests a broader challenge for the beverage industry, potentially benefiting companies better positioned for a value-conscious market.

Published: October 7, 2025

Explore Basket

Which Baskets Do They Appear In?

Beverage Stocks: Could Economic Headwinds Hit Returns?

Constellation Brands surpassed Q2 earnings expectations but trimmed its full-year forecast, signaling that economic headwinds are impacting consumer spending on alcohol. This development suggests a broader challenge for the beverage industry, potentially benefiting companies better positioned for a value-conscious market.

Published: October 7, 2025

Explore Basket

Discover More Comparisons

British American Tobacco vs Altria

Walmart vs Altria

Honeywell vs Altria

Honeywell vs Altria: Business comparison snapshot

AB InBev vs Altria

Comparison Snapshot

Why It's Moving

BUD Stock Climbs Amid Steady Gains and Recent Company Updates

Altria's Stock Powers Through Seven Straight Gains on FDA Green Light Momentum.

BUD Stock Climbs Amid Steady Gains and Recent Company Updates

Altria's Stock Powers Through Seven Straight Gains on FDA Green Light Momentum.